Articles / 2
The TRAILBLAZER-ALZ 2 study (NCT04437511) demonstrated significant clinical benefits of donanemab-azbt in early symptomatic Alzheimer disease (AD). Here are the key findings:Efficacy OutcomesCognitive & Functional....
To minimize adverse reactions when administering Donanemab-azbt (Kisunla), follow these evidence-based protocols:Pre-Infusion PreparationBaseline Assessments:Perform APOE ε4 genotyping (higher ARIA risk in homozygotes).Obtain a brain MRI....
The criteria for stopping Donanemab-azbt (Kisunla) therapy are primarily based on amyloid plaque reduction and safety monitoring, as outlined in clinical guidelines and prescribing information:Primary....
Donanemab-azbt (Kisunla) demonstrates distinct advantages and trade-offs compared to other Alzheimer's treatments, particularly monoclonal antibody therapies like lecanemab and aducanumab. Here's a structured comparison:Mechanism of....
Frequent Adverse ReactionsAmyloid-Related Imaging Abnormalities (ARIA)ARIA-Edema (ARIA-E): Temporary brain swelling (24% incidence), often asymptomatic but may cause headaches, dizziness, or confusion[2][3][4].ARIA-Hemosiderin Deposition (ARIA-H): Microhemorrhages (25%)....
Learn about the Hepatitis B Surface Antibody (HBsAb) test, its role in determining immunity to Hepatitis B, and how positive or negative results guide vaccination and infection status.
TPF Induction Chemotherapy in Head and Neck CancerBased on the TAX 324 study published in NEJM, the following represents a comprehensive treatment protocol for TPF....
Signup for the newsletter
Stay up to date with new articles.
Published with
Typeflo